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H I G H L I G H T S
• A health-related outcomes set has been developed for familial hypercholesterolemia (FH) patients.• This set contained both outcomes defined by health care professionals as patient-related outcomes (PROMS).• The response rate of the PROMS was 81.4%, implicating high acceptance.• Sufficient knowledge of a patient was associated with better health-outcomes.
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A B S T R A C T
Background and aims: Familial hypercholesterolemia (FH) is the most common hereditary lipid disorder re-
quiring life-long treatment to prevent cardiovascular disease. A recent concept in healthcare is not only to focus
on outcomes defined by healthcare professionals, but also take Patient-Reported Outcomes Measures (PROMs)
into account. The aim of this study is (1) to describe the development and first results of a health-related
outcomes set including PROMs for FH patients and (2) investigate the influence of patient knowledge on health-
related outcomes.
Methods: A multidisciplinary group of FH experts, in collaboration with a sounding board of FH patients
(n = 166), developed a health-related outcomes set containing the domains: medication adherence (MARS-5),
smoking, self-efficacy and self-management, quality of life (QOL) (EQ-5D-5L), reported adverse drug reactions,
lipid outcome measures, and FH and cardiovascular risk factor knowledge. Knowledge scores ranged from 0 to
10. Two groups were created: Insufficient knowledge (INSUF) (< 7.5), and Sufficient knowledge (SUF) (≥7.5).
Results: The response rate of the questionnaires was 81.4% (n = 429), implicating acceptance of PROMs. In
general, FH patients showed good knowledge, high QOL and were adherent to medication. However, the INSUF
group had higher triglycerides levels (1.0 vs 0.9, p < 0.05), lower QOL (0.89 [0.79, 1.00] vs 0.89 [0.85, 1.00],
p < 0.05), were more often smokers (14% vs 7%, p < 0.05) and reported more adverse drug reactions (62% vs.
49%, p < 0.05).
Conclusions: A health-related outcomes set for FH patients, including PROMs, has been developed, which shows
that insufficient knowledge of FH is negatively related to health outcomes. Improving patients’ knowledge of FH
may lead to better health.
1. Introduction
Cardiovascular disease (CVD) is the leading cause of mortality in the
world [1]. Its burden on society is still increasing in terms of costs and
years of life lost [1,2]. The most common hereditary cause of early-
onset CVD is familial hypercholesterolemia (FH) [3]. Recent evidence,
e.g. from the Netherlands and Denmark, showed that FH is prevalent in
approximately 1: 250 in the general population [4,5]. FH patients have
elevated low-density lipoprotein cholesterol (LDL-C) levels from birth
onwards due to a genetic defect influencing the LDL metabolism pre-
dominantly in the LDLR, APOB, or PCSK9 gene [6,7]. Inheritance of the
mutation generally occurs in an autosomal dominant pattern. Extensive
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years of untreated elevated LDL-C levels lead to an increased risk of
accelerated atherosclerosis and premature CVDs [6,8]. Hence, starting
treatment early on in life is critical. The main treatment of FH consists
of the combination of a healthy lifestyle and lipid-lowering medication
(e.g. statins, ezetimibe, or PCSK9 inhibitors). It is important not only to
focus on clinical outcomes such as LDL-C levels, but also on health-
related outcomes such as quality of life. As the majority of patients does
not notice any physical symptoms, it is essential that FH patients un-
derstand why it is worthwhile to lower their LDL-C levels to optimize
adherence [8–10]. Therefore, their understanding of FH as well as
cardiovascular risk factors and how to maintain a healthy lifestyle is
imperative. To evaluate the value of FH care, relevant health-related
outcomes need to be identified and measured. This approach fits with
the principle of value-based healthcare (VBHC), which defines value for
the patient by outcomes that matter to the patient over the costs ne-
cessary to achieve these outcomes [11]. To our knowledge, currently no
health-related outcome set, nor patient-reported outcome measure-
ments (PROMs) have been defined for FH patients. Hence the aims of
this study are (1) to develop a set of outcome measures including
PROMs for FH patients as basis for a future VBHC framework (2) to
analyse the influence of the FH patient's knowledge on the measures of
the health-related outcome set.
2. Materials and methods
2.1. Objectives
The purpose of developing an outcome measurement set for FH
patients is to identify outcomes that matter to them. To measure these
outcomes systematically, adequate instruments need to be identified.
Data can then be collected and used in clinical practice and for analysis
to determine possible improvements. This could lead to more value for
the patient.
2.2. Design and cohort definition
The present study has a descriptive design and complies with the
Declaration of Helsinki. We submitted our protocol to the Medical
Ethics Committee of Erasmus MC (METC) and received a waiver for
METC evaluation (MEC20190555). The following inclusion criteria for
participation were defined: (1) FH patients with a confirmed hetero-
zygous pathogenic mutation in the LDLR, APOB or PCSK9 gene and (2)
above the age of 18 years. Homozygous FH patients, having a more
severe disease and different treatment modalities, were excluded.
Clinically diagnosed FH patients with a score of ≥6 based on the Dutch
Lipid Clinic Network [12] without a pathogenic mutation in the
aforementioned genes were also excluded.
2.3. Working group
At Erasmus University Medical Center (Erasmus MC), Rotterdam,
the Netherlands, a working group of FH experts was established con-
sisting of: an internist vascular medicine specialized in lipid disorders,
nurse practitioner, 2 specialized FH nurses, and an FH patient re-
presenting the Dutch national FH patient support group “Harteraad”.
The VBHC expert team of Erasmus MC, including a health psychologist,
guided the working group through an institutional, standardized pro-
cess [13].
2.4. Development of the outcome set
The development of FH specific patient outcome measures was
structured according the blueprint previously described [13]. The
working group convened for 5 sessions between November 2015 and
March 2016. After discussing the FH patient journey in detail, possible
outcomes were brainstormed, taking into account pre-existing
knowledge and personal expertise, guidelines from literature, and di-
mensions of the disease such as the effect on the patient's direct en-
vironment and (in)visible burdens of FH. Also, possible relevant initial
patient conditions were discussed for risk stratification. Having iden-
tified potential outcomes and patient conditions, group members in-
dividually scored and ranked them on a scale from 0 to 5 (with 5 being
most important).
Outcomes were scored on (1) relevance, (2) impact on patient, and
(3) frequency. For initial patient conditions, relevance for risk adjust-
ment and frequency were scored. Also, an online survey was sent out to
patients (N = 372) between the 24th of December, 2015 and 5th of
January, 2016 with questions regarding the same possible outcomes to
get the patients’ opinions on what matters to them. This resulted in 166
(44,6%) responses. Results of the survey were discussed in the working
group in relation to the prioritized outcomes. After reaching consensus
on both the outcomes and initial patient conditions, possible measuring
instruments were discussed and agreed upon. In March 2017, the
standard set was implemented in the FH clinic at Erasmus MC. FH
patients received a link by email containing the FH outcomes ques-
tionnaires. If the questionnaires were not completed, they were re-sent
twice. The healthcare professional discussed the answers of the ques-
tionnaires with the patients during the out-patient clinic visit and used
this to customize the recommendations and treatment plan of the pa-
tients.
2.5. FH patient outcome measures
The final FH patient outcome set contains the following domains:
medication adherence, smoking, self-efficacy and self-management,
quality of life, FH and cardiovascular risk factor knowledge, reported
adverse drug reactions and lipid outcome measures (Fig. 1).
2.5.1. Medication adherence
The Medication Adherence Report Scale (MARS-5) was selected for
medication adherence. The MARS-5 questionnaire has been employed
before in FH research and validity as well as reliability of MARS-5 has
Fig. 1. Health-related outcome set for patients with familial hypercholester-
olemia.
FH: Familial hypercholesterolemia, SE: self-efficacy, VAS: Visual Analogue
Scale, EQ-5D-5L: EuroQol 5D with 5-point Likert scale, BMI: Body Mass Index.
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been found acceptable [14,15]. MARS-5 contains questions about e.g.
forgetting medication, changing dosage of the medication, and decision
to disregard an intake.
2.5.2. Smoking
Regarding smoking, the clinical building block tobacco use ques-
tionnaire was used, which was developed by the Dutch Centre of ex-
pertise for eHealth [16]. Besides being a case-mix variable, smoking
was selected as an outcome parameter, since smoking prevention and
guidance in smoking cessation is regarded as part of FH care [17].
2.5.3. Self-efficacy and self-management
The self-efficacy questionnaire covers aspects such as motivation
and self-management regarding medication, smoking, diet, exercise,
weight, and overall general self-management. A pre-existing validated
self-efficacy questionnaire was not available for FH patients. The
questionnaire used in the current outcome set is based on the self-ef-
ficacy questionnaire implemented in the research by Sol et al. [18]
investigating self-efficacy in vascular patients, which was derived from
the Diabetes Management Self-Efficacy Scale (DMSES) for diabetic pa-
tients, and was revised for FH patients, including motivation questions.
2.5.4. Quality of life (EQ5D)
The EuroQol 5D (EQ5D) measurement, which is widely used in
cardiovascular research [19], was selected to measure QOL along with
the visual analogue scale (VAS). The 5-point Likert scale was preferred
above the 3-point version since it has better discriminatory power [20].
Validity and reliability of this measurement has proven to be high in the
cardiovascular field [19].
2.5.5. Knowledge survey FH
The working group developed questions for the knowledge survey
on FH. This survey contains questions regarding various cardiovascular
risk factors important for FH patients. In total, patients are asked 10
questions concerning knowledge about the cause and inheritance pat-
tern of FH, meaning and interpretation of lipid levels, medication use,
body mass index (BMI), blood pressure, and exercise. Patients could
score full or half points, resulting in an end score between 0 and 10
points in total.
2.5.6. Reported adverse drug reactions
Reported adverse drug reactions of medication were determined per
patient by questioning whether patients experienced physical or mental
symptoms which they attributed to the use of medication.
2.5.7. Other relevant outcomes
Other relevant outcomes included are measurements such as LDL-C
and ApoB concentrations as well as BMI and blood pressure, which
were assessed during routine check-up.
2.5.8. Initial patient conditions
Important initial patient conditions (IPCs) for defining the case mix
were: sex, age, date of FH diagnosis, starting date lipid-lowering
treatment, socioeconomic status (SES), untreated LDL-C levels, self-re-
ported adverse drug reactions, BMI, DNA-mutation, diabetes, hy-
pertension, status CVD, smoking, and family history of premature CVD.
For on-going patient conditions (OPCs) the following variables are
updated every year after IPC (t0): LDL-C level, adverse drug reactions,
BMI, diabetes, hypertension, CVD, and family history of premature
CVD. SES scores based on postal codes for 2017 are available online and
are provided by the Netherlands Institute for Social Research [21]. SES
scores are calculated per neighbourhood using: mean annual income
per household, percentage of persons with a low income, percentage of
lower-educated people, and the percentage of unemployed people in a
neighbourhood. Average SES score in the Netherlands is 0 with a
standard deviation (SD) of 1.
2.6. Statistical analyses
All analyses were performed in SPSS version 24 for Windows.
Baseline characteristics of the respondents were compared to the non-
respondents as well as for the different knowledge groups. Because all
data distributions were abnormal, analyses were done using Mann-
Whitney and Chi-squared tests. Results were therefore mentioned in
terms of medians with interquartile ranges [IQR] or in the case of ca-
tegories in numbers and percentages. Statistical significance threshold
was set at p < 0.05. Looking at the distribution of the knowledge
scores, knowledge was deemed sufficient at the median knowledge
score of ≥7.5. Consequently, patients with a score of ≥7.5 were placed
in the sufficient knowledge group and patients with a score< 7.5 in the
insufficient knowledge group. Further sub-analyses were performed
using aforementioned statistical tests or Spearman's rho correlation.
3. Results
3.1. Study population
Between March 2017 and early October 2018, 540 FH patients re-
ceived the questionnaires of which 13 did not meet the inclusion cri-
teria and were excluded (Fig. 2). Of the 527 eligible patients, 429 filled
in the questionnaire, resulting in a response rate of 81.4%.
Supplemental Table 1 shows the baseline characteristics of responders
and non-responders (Appendix A). Respondents were significantly older
than the non-responders (49 years vs. 41 years, p = 0.001), had higher
SES scores (0.2894 vs 0.1164, p = 0.036), and had higher HDL-C and
lower LDL-C and ApoB levels.
Median age of respondents was 49 years [35, 59] and 48% were
male. Median SES score was 0.2894 [-0.3228, 0.9151], which is slightly
above the Dutch average. Baseline characteristics were compared for
the different knowledge groups (Table 1). The sufficient knowledge
group (SUF) had a significantly lower median age compared to the
insufficient knowledge group (INSUF) (51 vs 48 years, p = 0.022). In
general, no significant differences were found between the groups re-
garding medication use.
A closer look at the results of the knowledge questionnaire showed
that all respondents scored best on questions about FH specifically
(Appendix B). With 97.2% of the patients knowing what the cause is of
FH (question 7) and 91.6% knowing about FH's heritability (question
1). Respondents scored worst on questions 3 and 5, which concerned
Fig. 2. Flowchart of inclusion process of the study.
FH: familial hypercholesterolemia.
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knowledge about “bad” cholesterol measures and frequency of forget-
ting medication respectively.
Comparing the outcomes, several domains differed significantly
between the SUF and INSUF. BMI was significantly lower in the SUF
compared to the INSUF (25.28 kg/m2 vs. 26.33 kg/m2, p = 0.022). For
all three domains of self-management (diet, exercise and weight) the
SUF had lower, thus better, scores (Table 2). Regarding lipid levels,
only triglycerides were lower in the SUF (0.90 mmol/L vs. 1.00 mmol/
L, p = 0.003). In the INSUF significantly more patients reported to have
experienced adverse drug reactions from statins in comparison with the
SUF (62.3% vs 48.8%, p = 0.005) and were more often smokers (13.6%
vs. 6.9%, p = 0.022). QOL represented by the EQ-5D-5L index score,
was higher in the SUF than in the INSUF (0.8872 [0.7877,1.000] vs.
0.8872 [0.8499, 1.0000], p = 0.048).
A sub-analysis for the EQ-5D subdomains showed that mobility was
good in 88% of the SUF versus 74% of the INSUF (1.0 [1.0–1.0] vs 1.0
[1.0–2.0], p = 0.002).
A correlation analysis indicated a moderate strength of association
between general self-efficacy with self-efficacy regarding medication
use, smoking habits, healthy food intake, exercise, and healthy weight
(respectively: 0.333, 0.413, 0.398, 0.381, 0.452; p = 0.000 for all
correlations). Besides, significant associations were found between
whether the patient's BMI<25 kg/m2 and self-efficacy of weight
(0.444, p < 0.001) as well as between whether the patient smoked and
self-efficacy of smoking (0.678, p < 0.001).
4. Discussion
This is the first study to identify and describe the development of a
health-related outcome set for FH patients according to a predefined
method involving both health-care professionals as patients. The result
was a health-related outcome set containing the domains: medication
adherence, smoking, self-efficacy and self-management, quality of life,
reported adverse drug reactions and lipid outcome measures, and FH
and cardiovascular risk factor knowledge. The acceptance of this
outcome set was high with a response rate of 81%. Moreover, we
showed that a patients’ knowledge on FH and cardiovascular risk fac-
tors is associated with better health outcomes.
4.1. Health-related outcome set
The importance of VBHC is that health-related outcome sets are
being developed to measure all outcomes relevant for the patient. The
data of these outcome sets not only give insights in the current care
delivered, but also will lead to improvements for the future, and more
personalized care. In this study, all relevant outcomes for FH patients
were developed by a multidisciplinary team including patients. Patient
behaviours such as adherence and smoking were designated by both the
multidisciplinary team and the sounding board of FH patients as health-
related outcomes. These factors are of great importance as they have an
adverse effect on their current health situation. FH healthcare profes-
sionals could then use the patient's outcome scores to customize re-
commendations and treatment. The scores can be used to compare the
scores within one patient over the years, or to compare between pa-
tients in one or even multiple centres. A study in Finnish statin users
found that a 10% increase in statin use was associated with a 5% de-
crease of the risk of coronary heart disease mortality [22]. In the Danish
population, people with definite or probable FH had a higher odds ratio
of developing coronary artery disease when they are not receiving lipid-
lowering medication in comparison to when they are on lipid-lowering
medication [23]. Moreover, recently we showed that in FH patients
using maximum statin therapy the risk of CVD was in particular related
to smoking underlying the importance of smoking as CVD risk factor in
FH patients [24].
Systematic (inter)national implementation of the FH outcome set
will also stimulate benchmarking. All in all, having a clearly defined
outcome set for FH could help healthcare professionals in taking better
care of FH patients.
Table 1
Baseline characteristics of familial hypercholesterolemia patients per knowledge group.
Respondents Insufficient knowledge (n = 184) Sufficient knowledge (n = 245) p-valuea
Male, n (%) 206 (48.0) 94 (51.1) 112 (45.7) 0.27
Age (years), median [IQR] 49 [35, 59] 51 [37, 63] 48 [35, 57] 0.022*b
SES, median [IQR] 0.2894 [-0.3228, 0.9151] 0.3249 [-0.4083, 0.9009] 0.2609 [-0.3230, 0.9187] 0.71b
Current smoking, n (%) 42 (9.8) 25 (13,6) 17 (6.9) 0.022*
Diabetes mellitus II, n (%) 17 (4.0) 8 (4.3) 9 (3.7) 0.072
Hypertension, n (%) 65 (15.2) 31 (16.8) 34 (13.9) 0.39
CVD, n (%) 79 (18.5) 38 (20.7) 41 (16.8) 0.31
CVD in family members, n (%) 226 (56.1) 104 (60.8) 122 (52.6) 0.10
Years of statin use, median [IQR] 7 [4.5, 10] 7 [4, 10] 7 [5, 10] 0.34b
On lipid-lowering medication, n (%) 418 (97.4) 97.8% 97.1% 0.65
Atorvastatin 132 (30.8) 57 (31.0) 75 (30.6) 0.87
Rosuvastatin 216 (50.3) 93 (50.5) 123 (50.2) 0.38
Simvastatin 31 (7.2) 14 (7.6) 17 (6.9) 0.80
Pravastatin 5 (1.2) 4 (2.2) 1 (0.4) 0.25
Fluvastatin 2 (0.5) 2 (1.1) 0 (0.0) 0.10
Ezetimibe 320 (74.6) 135 (73.4) 185 (75.5) 0.61
Alirocumab 51 (11.9) 26 (14.1) 25 (10.2) 0.05
Evolocumab 51 (11.9) 24 (13.0) 27 (11.0) 0.52
Lab, median [IQR]
Tot-C 4.30 [3.80, 5.00] 4.4 [3.8, 5.2] 4.3 [3.7, 4.8] 0.24b
HDL 1.37 [1.13, 1.60] 1.36 [1.09,1.63] 1.39 [1.14, 1.59] 0.33b
ApoB 0.91 [0.77, 1.08] 0.92 [0.78, 1.14] 0.90 [0.77, 1.06] 0.20b
TG 0.95 [0.73, 1.30] 1.00 [0.77, 1.46] 0.90 [0.70, 1.24] 0.003*b
Socioeconomic status (SES): Mean (SD) Dutch population is 0 (−1,1).
CVD: cardiovascular disease; Lah: laboratorium serum levels of; Tot-C: total cholesterol, HDL: HDL-cholesterol, ApoB: apolipoprotein B, TG: triglycerides.
* Significant (p < 0.05).
a Chi-squared test was used for all variables unless indicated otherwise (b).
b Mann-Whitney test was performed.
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4.2. Importance of knowledge
In previous studies it was concluded that the knowledge of FH in
health care professionals was suboptimal [25–28]. A study in Saudi-
Arabia found that 67% of healthcare professionals was not aware of FH
heritability and that also other knowledge aspects, such as LDL-C target
levels, were lacking [25]. Another study with data from ten countries in
the Asia-Pacific, also found several areas of knowledge to be in-
sufficient, in particular recognition of FH's heritability differed per
country with lowest percentage being 26% till highest 61% [26]. To be
able to educate FH patients and their families it is essential that
healthcare professionals have basic knowledge on the subject.
Previous research showed that patient activation, including a pa-
tient's disease knowledge, is associated with better outcomes [29]. In
studies with CVD patients, patient education led to better self-care
behaviours [30,31]. As FH is a predominantly autosomal dominant
condition, patients' knowledge that the risk of having FH is 50% in first
degree family members is important to mobilize family members to
attend an FH clinic to be tested on FH. In our study, almost all patients
(91.6%) were aware of the inheritance pattern which is higher than in
the previously mentioned studies on knowledge in health-care
professionals. The high awareness in our patients is likely because our
clinic is a specialized FH clinic and patient education is one of our
priorities. This underlies the importance of FH patients attending spe-
cialized FH clinics.
4.3. FH patients vs general populations
The mean VAS score for QOL in the Dutch population is 80.6 and
the EQ-5D index value 0.869 for the 5L version [32]. The median scores
in the FH respondent population are respectively 80 and 0.8872, in-
dicating that the QOL of FH patients in our clinic seems to not be ne-
gatively affected. The same applies for the measured self-efficacy,
which are all between the highest score, being 1 and 2. We found that
the EQ-5D index level was significantly lower in the INSUF group
compared to the SUF group (0.8872 [0.7877, 0.1.000] vs 0.8872
[0.8499, 1.0000], p = 0.048). The mean EQ-5D index value of the
INSUF group (0.8497) is much lower than the median and below the
Dutch population average, indicating potential room for improvement.
Compared to the Dutch population BMI, overweight and obese per-
centages were slightly higher in our patients (42.1% and 16.3%)
compared to the Dutch population age 40–50 years (38.5% and 14.9%)
Table 2
Outcome scores of familial hypercholesterolemia patients per knowledge group.
Insufficient knowledge
(n = 184)
Sufficient knowledge
(n = 245)
p-valueb
Medication adherence, median [IQR]
MARS-5 value 24.0 [23, 25] 24.0 [23, 25] 0.34
Self-efficacy, median [IQR]
Medication 1.00 [1.00, 1.50] 1.00 [1.00, 1.50] 0.94
Smoking 1.50 [1.00, 2.50] 1.50 [1.00, 2.00] 0.15
Diet 1.67 [1.33, 2.33] 1.67 [1.00, 2.00] 0.011*
Exercise 1.33 [1.00, 2.00] 1.00 [1.00, 1.67] < 0.001*
Weight 1.67 [1.00, 2.33] 1.33 [1.00, 2.00] 0.018*
General 2.00 [1.00, 2.00] 2.00 [1.00, 2.00] 0.32
Quality of Life, median [IQR]
EQ5D Index value 0.8872 [0.7877, 1.0000] 0.8872 [0.8499, 1.0000] 0.048*
VAS value 80 [70, 90] 81 [74, 90] 0.44
Adverse drug reactions, n (%)
Side-effects lipid-lowering
medication
114 (62.3) 119 (48.8) 0.005*a
Smoking, n (%)
Current smoker 25 (13.6) 17 (6.9) 0.022*a
FH Knowledge, median [IQR]
Overall knowledge 6.5 [5.5, 7.0] 8.0 [7.5, 8.5] < 0.001*
FH specific knowledge 6.7 [5.8, 7.5] 8.3 [7.5, 9.2] < 0.001*
General knowledge 5.0 [5.0, 7.5] 7.5 [5.0, 7.5] < 0.001*
Measurements, median [IQR]
Lab
LDL-cholesterol 2.75 [2.31, 3.52] 2.69 [2.21, 3.32] 0.29
Blood pressure (mmHg)
Systolic pressure 126 [115, 135] 127 [117, 136] 0.51
Diastolic pressure 78 [70, 84] 76 [70, 82] 0.84
BMI (kg/m2) [IQR]
BMI 26.33 [23.51, 29.34] 25.28 [22.81, 22.78] 0.022*
MARS-5: Medication Adherence Report Scale.
Self-efficacy: scale from 1 to 5, 1 being the best result.
EQ-5D-5L index-value: EuroQol 5D: scale from -0.028 to 1.
Visual Analogue Scale (VAS): from 0 to 100.
FH knowledge: scale from 0 to 10.
BMI: Body Mass Index.
* Significant (p < 0.05).
a Chi-squared test was used.
b Mann-Whitney test was performed unless stated otherwise (a).
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[33]. On the other hand, the percentage smokers in our study popula-
tion was much lower than in the general Dutch population ≥18 years
(9.8% vs 23.1%) [33]. In our clinic, education about smoking preven-
tion and cessation is explicitly part of the care provided to FH patients.
These results indicate that this active approach is effective.
As most of FH patients are asymptomatic it is a challenge to opti-
mize preventive treatment and it essential that the individual patient
sees the necessity of investing in their health. EHealth could play an
important role in improving cardiovascular prevention by continuously
offering patients information and reminding the importance of treat-
ment [34].
4.4. Strengths and weaknesses
Strengths of this study are the large sample size and high response
rate. However, ideally all patients would fill in the questionnaires.
Questionnaires were sent by email which might be a hurdle for patients
lacking digital skills. To further increase the response rate, we now offer
FH patients visiting the FH clinic the option to fill in the questionnaires
on a tablet assisted by nurses while waiting.
Another limitation of this study is that it has been developed and
executed in a single FH centre. Implementation in other FH centres
could support or differentiate the results leading to generalizable
findings. Furthermore, the average SES score of the patients attending
our clinic proved to be above the national average indicating that we
miss FH patients with lower SES. This implies inequity in the care of FH
patients and should lead to a more active policy for attracting specifi-
cally patients with low SES, especially as low SES is associated with
having more modifiable and behavioural risk factors for CVD [35].
4.5. Conclusions
Relevant to the concept of value-based healthcare, a health-related
outcomes set, including PROMs, has been developed for heterozygous
FH patients. First results of this set have been measured in 429 FH
patients from the Netherlands and show valuable insights for FH care
and how to improve this. We found that a patient's knowledge of FH has
an influence on outcomes and therefore on a patient's health. Therefore,
this study concludes that stimulating patients' FH knowledge may im-
prove value for the FH patient.
Supporting patients and improving insufficient knowledge of pa-
tients as a part of clinical practice, may lead to better outcomes. To
optimize the outcome set, further research into its use over a longer
period of time and in more FH centres is needed. Further investigation
is needed in non-respondents and the inequity with respect to FH pa-
tients not attending the clinic. Also, more work is needed on the effects
of knowledge interventions and the role eHealth could play.
The outcome set developed can be used as a tool in FH management
to capture useful data on the patient in an organized way. In addition,
implementation of the outcome set is important for future bench-
marking with other FH centres to improve FH care.
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